Trial Watch: Peptide-based anticancer vaccines

Jonathan Pol, Norma Bloy, Aitziber Buqué, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

101 Citaten (Scopus)


Malignant cells express antigens that can be harnessed to elicit anticancer immune responses. One approach to achieve such goal consists in the administration of tumor-associated antigens (TAAs) or peptides thereof as recombinant proteins in the presence of adequate adjuvants. Throughout the past decade, peptide vaccines have been shown to mediate antineoplastic effects in various murine tumor models, especially when administered in the context of potent immunostimulatory regimens. In spite of multiple limitations, first of all the fact that anticancer vaccines are often employed as therapeutic (rather than prophylactic) agents, this immunotherapeutic paradigm has been intensively investigated in clinical scenarios, with promising results. Currently, both experimentalists and clinicians are focusing their efforts on the identification of so-called tumor rejection antigens, i.e., TAAs that can elicit an immune response leading to disease eradication, as well as to combinatorial immunostimulatory interventions with superior adjuvant activity in patients. Here, we summarize the latest advances in the development of peptide vaccines for cancer therapy.

Originele taal-2Engels
Nummer van het tijdschrift4
StatusGepubliceerd - 2015
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Trial Watch: Peptide-based anticancer vaccines'. Samen vormen ze een unieke vingerafdruk.

Citeer dit